Latigo Biotherapeutics, Inc. Common Stock (LTGO) — Cash Flow-to-Debt Ratio
Latigo Biotherapeutics, Inc. Common Stock (LTGO) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2026, meaning its operating cash flow of $-21.28 Million could theoretically repay 0% of its total liabilities ($340.84 Million) in one year. See Latigo Biotherapeutics, Inc. Common Stoc (LTGO) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Latigo Biotherapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Latigo Biotherapeutics, Inc. Common Stock across 2 annual periods. See how leveraged is Latigo Biotherapeutics, Inc. Common Stoc's balance sheet to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Latigo Biotherapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see LTGO cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.32x | $-97.56 Million | $307.19 Million | ▲ +5.0% |
| 2024 | -0.33x | $-50.95 Million | $152.46 Million | — |